In a groundbreaking study published in Cell Research, a team of scientists led by Cheng, Zhou, and Huang have unveiled detailed structural and functional mechanisms by which the hepatitis B virus (HBV) protein HBx interacts with the host protein Smc6, advancing our understanding of viral inhibition and opening new avenues for targeted antiviral therapies. This research addresses a crucial hurdle in HBV biology, namely how the virus subverts host cellular machinery to maintain chronic infection, offering fresh insights that may revolutionize treatment paradigms for millions afflicted by this pervasive virus worldwide.
Chronic HBV infection remains a global health challenge, impacting nearly 300 million individuals and constituting a leading cause of liver cirrhosis and hepatocellular carcinoma. The virus’s persistence largely hinges on its ability to evade immune responses and manipulate host cellular factors. Central to this is the HBV regulatory protein HBx, which exerts pleiotropic effects, including epigenetic modulation and degradation of host restriction factors. Notably, the structural maintenance of chromosomes hinge subunit Smc6 represents a key player whose targeted degradation by HBx is critical for viral replication, but the precise molecular underpinnings of this interaction have remained elusive until now.
Using state-of-the-art cryo-electron microscopy (cryo-EM) and biochemical assays, the researchers resolved the intricate interface between HBx and the Smc5/6 complex at near-atomic resolution. Their data reveal that HBx specifically binds to a unique pocket within the Smc6 subunit, inducing conformational changes that prime it for ubiquitin-mediated proteasomal degradation. This selective targeting dismantles the host’s antiviral restriction machinery, allowing HBV covalently closed circular DNA (cccDNA) to evade repression and perpetuate infection. The elucidation of this molecular handshake is a pivotal step toward disrupting the viral life cycle with unprecedented precision.
Beyond structural insights, the team probed the functional ramifications of HBx-Smc6 engagement in hepatocyte models. By engineering HBx mutants deficient in Smc6 binding, they observed a marked reduction in viral replication, underscoring the essentiality of this interaction. Moreover, reintroduction of Smc6 into infected cells curtailed cccDNA transcriptional activity, affirming the protein’s intrinsic antiviral capacity when spared from HBx-induced degradation. These functional validations firmly establish HBx’s role as a viral antagonist of Smc6 and highlight Smc6 as a promising therapeutic target.
The study further delineates the mechanism by which HBx recruits the cellular ubiquitin E3 ligase complex CRL4 to Smc6, effectively hijacking the host’s protein degradation pathway. Detailed biochemical reconstitution experiments demonstrated that HBx acts as an adaptor, bridging CRL4 to Smc6 and catalyzing site-specific ubiquitination. Importantly, the authors identified critical residues on HBx required for ligase recruitment, providing potential molecular handles for drug design aimed at interrupting this tripartite complex formation.
Intriguingly, comparative structural analysis revealed substantial conservation in the mode of interaction between HBx and Smc6 across multiple HBV genotypes, suggesting that therapeutics targeting this interface could possess broad-spectrum efficacy against diverse viral strains. This evolutionary conservation hints at the indispensability of HBx-mediated Smc6 degradation in HBV’s survival strategy, reinforcing the clinical relevance of these findings.
The precision with which HBx subverts Smc6 function exemplifies the sophisticated viral tactics evolved to evade host defenses. The researchers emphasize that therapeutic interventions aimed at stabilizing Smc6 or blocking HBx binding could restore the host’s antiviral barrier and suppress viral persistence. Their work provides a blueprint for the rational design of small molecules or biologics capable of stabilizing Smc6 or preventing ubiquitin ligase recruitment, highlighting a novel therapeutic avenue distinct from current nucleos(t)ide analog treatments.
In addition to therapeutic implications, this research advances fundamental virology and chromatin biology by illuminating how viral proteins target chromosomal maintenance complexes to subvert host epigenetic regulation. The Smc5/6 complex plays a broader role in genome stability beyond viral restriction, and its perturbation by HBx may contribute to oncogenic processes associated with chronic HBV infection. Understanding these intersecting pathways unlocks new questions about virus-host coevolution and cancer pathogenesis.
The study also tackles technical challenges inherent to studying viral protein-host complexes, leveraging innovative labeling and stabilization techniques to capture transient interactions. This methodological advance heralds a new era of structural virology, facilitating atomic-level visualization of dynamic viral-host interfaces previously intractable to conventional methods. The integrative approach combining structural biology, biochemistry, and cell biology sets a new standard for dissecting complex viral mechanisms.
With the rising global burden of HBV infection and limited curative options, the urgency for novel therapeutic targets cannot be overstated. The identification of HBx-Smc6 interaction as a linchpin for viral persistence represents a paradigm shift with translational potential. Pharmaceutical pipelines can now integrate these findings to develop next-generation antivirals that complement existing treatments by reinstating the host’s intrinsic antiviral functions.
Experts in the field have hailed the study as a landmark breakthrough. Dr. Anne-Marie Larsen, a leading HBV researcher not involved in the study, commented, “This research elegantly deciphers the molecular crosstalk exploited by HBV and illuminates a high-value target that could be the Achilles’ heel of chronic HBV infection. It paves the way for therapeutic strategies that go beyond viral suppression to achieve functional cure.”
The implications of this work extend beyond HBV, as similar mechanisms of viral protein hijacking of host chromosomal complexes are observed in other persistent viral infections. The principles uncovered here may inform antiviral strategies against related viruses such as hepatitis C, herpesviruses, and retroviruses, broadening the impact of these findings in infectious disease research.
Moving forward, the authors aim to translate their discoveries into clinical candidates by screening compound libraries for inhibitors of the HBx-Smc6 interaction and assessing their efficacy in animal models of HBV infection. Parallel investigations will explore the broader cellular consequences of stabilizing Smc6, ensuring safety and minimizing off-target effects. This bench-to-bedside trajectory underscores the translational promise of structural virology.
In sum, this study by Cheng et al. represents a tour de force in molecular virology and structural biology, unraveling the elusive mechanism by which HBx undermines host antiviral defenses through targeted Smc6 degradation. By mapping atomic details of a viral-host confrontation, the research charts a path toward innovative therapeutics aimed at eradicating chronic HBV infection—a goal of immense public health significance.
Subject of Research: Hepatitis B virus (HBV) interaction with host cellular machinery, specifically the structural and functional dynamics of the viral protein HBx targeting the Smc6 protein complex to facilitate viral persistence and replication.
Article Title: Structural and functional insights into HBx–Smc6 targeting for HBV inhibition.
Article References:
Cheng, T., Zhou, J., Huang, W. et al. Structural and functional insights into HBx–Smc6 targeting for HBV inhibition. Cell Res (2026). https://doi.org/10.1038/s41422-026-01251-7
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41422-026-01251-7
Tags: chronic hepatitis B treatment targetscryo-electron microscopy HBx-Sm6 complexepigenetic modulation in HBV infectionHBV host protein degradationHBV immune evasion molecular basisHBV-induced liver cirrhosisHBx Smc6 interaction mechanismshepatitis B virus protein structurehepatocellular carcinoma viral factorsmolecular biology of HBV persistencetargeted antiviral therapies HBVviral inhibition strategies HBV
